Reanalysis of Popular Antidepressant Trial Uncovers Reporting Flaws
Sep 16, 2025•8 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
- A reanalysis of a study found that fluoxetine alone showed no measurable benefit over placebo in treating adolescent depression after 12 weeks
- Researchers uncovered 11 additional suicide-related events that were hidden or misclassified, bringing the total to 21 serious incidents
- Statistical tactics and selective reporting made fluoxetine appear safer and more effective than it really was in clinical trials
- A different reanalysis mentioned that adverse events and many side effects were minimized or excluded from the original reports
- Improving gut health, getting regular exercise, undergoing therapy, and optimizing vitamin D are viable approaches for treating depression
For the best experience, listen in Metacast app for iOS or Android